If the dose limiting toxicities of vemurafenib in this trial are not prohibitive to its administration in children, then a possible next step will be to provide combination treatment of vemurafenib with concurrent external beam radiation in children with BRAF V600E-mutated high-grade gliomas, or recurrent BRAF V600E-mutated low-grade gliomas. The gene discussed is BRAF; the disease is central nervous system cancer.